What are the side effects of stopping fluoxetine (selective serotonin reuptake inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinuation Effects of Fluoxetine

Fluoxetine has minimal withdrawal symptoms compared to other SSRIs due to its very long half-life, making abrupt discontinuation relatively safe and well-tolerated. 1

Key Characteristics of Fluoxetine Discontinuation

Fluoxetine is uniquely protective against discontinuation syndrome because its active metabolite (norfluoxetine) has an elimination half-life that provides natural tapering over weeks, unlike shorter-acting SSRIs. 1

Minimal Withdrawal Profile

  • Abrupt discontinuation of fluoxetine produces few clinically significant symptoms in most patients, with only mild, self-limited lightheadedness or dizziness occurring in a small percentage of cases. 1

  • In controlled studies, patients who abruptly stopped fluoxetine after 12 weeks of treatment showed similar rates of new adverse events compared to those continuing treatment, with no cluster of symptoms suggesting a discontinuation syndrome. 1

  • Patient discontinuation rates related to adverse events were equivalent between those who stopped fluoxetine and those who continued it. 1

Rare Discontinuation Symptoms

When symptoms do occur, they may include:

  • Dizziness or incoordination (most common when symptoms occur). 2
  • Headaches. 2
  • Nausea. 2
  • Irritability. 2

Exceptional Cases

  • Delirium has been reported in isolated case reports following abrupt fluoxetine discontinuation, though this is extremely rare and atypical. 3

Comparison to Other SSRIs

Fluoxetine has significantly lower risk of discontinuation syndrome compared to paroxetine, fluvoxamine, sertraline, and venlafaxine, which commonly produce withdrawal symptoms. 4, 2, 5

  • Paroxetine, venlafaxine, and fluvoxamine produce frequent and sometimes severe discontinuation reactions, including psychological symptoms (anxiety, depression, confusion, irritability) and somatic symptoms (dizziness, nausea, headache). 2, 5

  • 86% of patients abruptly withdrawn from fluvoxamine developed new symptoms, with symptoms peaking at Day 5 post-discontinuation. 2

Clinical Recommendations

Fluoxetine can be stopped abruptly without tapering in most patients due to its pharmacokinetic properties providing natural dose reduction over weeks. 1

  • For patients switching from fluoxetine to another antidepressant, no washout period is typically needed, though the long half-life means fluoxetine effects persist for weeks. 1

  • General guideline for discontinuing antidepressants suggests tapering over 10 to 14 days to limit withdrawal symptoms, but this is less critical for fluoxetine specifically. 6

Important Caveats

  • Fluoxetine may offer a safety advantage for patients likely to miss doses due to travel or forgetfulness, as treatment interruption is better tolerated than with shorter-acting agents. 1

  • Do not confuse discontinuation symptoms with depression relapse—true discontinuation syndrome symptoms emerge within days and resolve spontaneously, while depression recurrence develops more gradually. 1

  • The very long half-life that protects against withdrawal also means side effects may persist for weeks after stopping, which can be problematic if switching medications or if side effects were the reason for discontinuation. 6

References

Research

Delirium following abrupt discontinuation of fluoxetine.

Clinical neurology and neurosurgery, 2008

Guideline

Escitalopram Side Effects and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Withdrawal reactions associated with venlafaxine.

The Australian and New Zealand journal of psychiatry, 1998

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.